GLG News by Bepotastine Experts for Allergic Conjunctivitis.: Opthalmologists

Vincent de LuiseAssistant Clinical Professor of Ophthalmology Yale University - CC

Technical analysis of multifocal lens implants (IOLs) and astigmatism lens implants (Toric IOLs)

July 14, 2009

Analysis of:FDA Approves Alcon's AcrySof® IQ ReSTOR® +3.0 D Intraocular Lens - New Lens Corrects For Cataracts With Presbyopia | www.medicalnewstoday.com

 There is a sea-change in cataract/lens implant (IOL) surgery.  More than ever before, patients with cataracts want to able to see well without the need for glasses or contact lenses. Standard IOLs give very good vision, but many patients have pre-existing astigmatism and need correction for that with a Toric IOL, and those who want to see well for distance and near will require either a multifocal IOL (Alcon ReStor, AMO ReZoom or Technis ZM900 IOL) or an accommodative IOL (Bausch and Lomb Crystalens).        Alcon's two IOLs, their  Acrysof Toric IOL for astigmatism, and their newest multifocal IOL, the Alcon ReStor +3.0 D are showing good usage      With respect to astigmatism, the two existing IOLs are the Staar Toric IOL and the Alcon Toric IOL, both of which work well. The multifocal Aspheric Alcon ReStor + 3.00 D is showing strong penetration because the + 3.00 D add allows for intermediate (computer vision) as well as near vision and less haloes and glare .

Vincent de LuiseAssistant Clinical Professor of Ophthalmology Yale University - CC

eye drop corticosteroids (topical steroids) for LASIK and cataract surgery and dry eye

June 23, 2009

Analysis of:steroids in eye surgery | www.siriontherapeutics.com

    There are several potent cortisteroids (steroids) in the form of eye drops, which ophthalmologists use daily to manage postoperative healing after LASIK surgery cataract surgery, and intraolcular lens implant surgery.  In addition, some steroid drops can be used for short intervals of time in managaing dry eye disease. These include pred forte (Allergan), omnipred (Alcon), Maxidex (Alcon), Lotemax (Bausch and Lomb) and Durezol (Sirion).     These steroid drops have slghtly different biochemical structures and side effect profiles. In general,the more potent the steroid, the more likely it has a side effect of intraocular pressure rise (glaucoma risk) and cataract formation. Durezol, a newer topical steroid from Sirion Therapeutics, has excellent potency and slightly less of a side effects. Lotemax (Bausch and Lomb) has found a niche in the management of dry eye disease, being used for short intervals (a few weeks) in dry eye management, as other drops such as restasis get on board.

Barry SchechterDirector of Cornea and External DiseaseFLORIDA EYE MICROSURGICAL INSTITUTE INC

Bausch makes foray into presbyopic arena

January 29, 2008

Analysis of:Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com

With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.

Barry SchechterDirector of Cornea and External DiseaseFLORIDA EYE MICROSURGICAL INSTITUTE INC

Newly identified risks for refractive surgery

April 16, 2007

Analysis of:Researchers report 13 cases of MRSA keratitis after laser refractive surgery | www.osnsupersite.com

Refractive surgery is taken for granted by patients to "get rid of their glasses and contact lenses". They rarely consider the possibility of loss of vision.

Barry SchechterDirector of Cornea and External DiseaseFLORIDA EYE MICROSURGICAL INSTITUTE INC

ISTA takes the lead in topical NSAID therapy

February 14, 2007

Analysis of:ISTA Pharmaceuticals Announces Positive Preliminary Xibrom Once-daily Formulation Clinical Results From U.S. Phase III Trials | pharmalive.com

There has been a sea change in the treatment of postoperative cataract patients. The addition of a nonsteroidal has significantly reduced postoperative complications such as edema, discomfort and inflammation.

Compliance with all medications is always an issue, and the use of a once daily medication potentially makes this a non-issue. I have been impressed with the BID Xibrom and my patients in the phase 3 trial did exceptionally well.

I expect that this will be well received, pending acceptance of formularies.

Vincent de LuiseAssistant Clinical Professor of Ophthalmology Yale University - CC

Pfizer Cut Issues and Observations

November 30, 2006

Analysis of:Pfizer to Cut Its U.S. Sales Force by 20% | www.nytimes.com

What is the effect of downsizing sales representatives on drug sales for Pfizer?

 

Barry SchechterDirector of Cornea and External DiseaseFLORIDA EYE MICROSURGICAL INSTITUTE INC

Additional Thoughts on Fusarium

May 10, 2006

Analysis of:Doubt Cast on Early Theory on Eye Infections | www.nytimes.com

Multiple species of Fusarium have been reported as pathogens.

Barry SchechterDirector of Cornea and External DiseaseFLORIDA EYE MICROSURGICAL INSTITUTE INC

ReStor gradually becoming more popular

May 10, 2006

Analysis of:Alcon Still Not Living Up to Valuation | www.fool.com

Dr Packer writes that the ReStor lens is taking time to catch on with cataract surgeons.

Page : 11 to 8 of 8